SUBSCRIBE
SUBSCRIBE
News   Policy

Regeneron Pharmaceuticals, Inc. Says FDA Extends Priority Review of CAPS Treatment

November 2, 2007 | 
1 min read
Nov 1 (Reuters) - Regeneron Pharmaceuticals Inc (REGN.O: Quote, Profile, Research) said U.S. regulators have extended the date for taking action on a priority review of the company's treatment for a rare chronic inflammatory disease known as CAPS.
Regulatory
Regeneron Pharmaceuticals, Inc. Food and Drug Administration (FDA)
MORE ON THIS TOPIC
World Management Team in office silhouette 3d rendering
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
 · 
6 min read
 · 
Lori Ellis
Contemporary art collage. Giang hand kicking office worker symbolizing dismissal. Unsuccessful employee. Job reduction. Concept of business, career, failure, success, troubles
Rare diseases
Ultragenyx Takes Second Hit as FDA Rejects Gene Therapy for Sanfilippo Syndrome
July 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Regulatory
FDA Mulls Speedier Reviews to Companies Willing To Lower Drug Costs
July 14, 2025
 · 
1 min read
 · 
Tristan Manalac
Contemporary art collage showing a hand giving a thumbs down surrounded by red arrows pointing down, concept of negative feedback and bad review
Complete response letters
Capricor Plunges on FDA Rejection of DMD Cell Therapy
July 11, 2025
 · 
3 min read
 · 
Tristan Manalac